These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24006850)

  • 1. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.
    Bismar TA; Alshalalfa M; Petersen LF; Teng LH; Gerke T; Bakkar A; Al-Mami A; Liu S; Dolph M; Mucci LA; Alhajj R
    BJU Int; 2014 Feb; 113(2):309-19. PubMed ID: 24006850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality.
    Bismar TA; Dolph M; Teng LH; Liu S; Donnelly B
    Eur J Cancer; 2012 Mar; 48(4):538-46. PubMed ID: 22300588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
    Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
    BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer.
    Kron K; Trudel D; Pethe V; Briollais L; Fleshner N; van der Kwast T; Bapat B
    Clin Cancer Res; 2013 Jul; 19(13):3450-61. PubMed ID: 23549870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease.
    Teng LH; Wang C; Bégin LR; Dolph M; Yilmaz A; Trpkov K; Donnelly B; Bismar TA
    Urology; 2013 Aug; 82(2):394-9. PubMed ID: 23746715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
    Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
    Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
    Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
    Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis.
    Gao X; Li LY; Zhou FJ; Xie KJ; Shao CK; Su ZL; Sun QP; Chen MK; Pang J; Zhou XF; Qiu JG; Wen XQ; Yang M; Bai XZ; Zhang H; Ling L; Chen Z
    Clin Cancer Res; 2012 Aug; 18(15):4163-72. PubMed ID: 22696228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers.
    Gasi Tandefelt D; Boormans JL; van der Korput HA; Jenster GW; Trapman J
    Eur Urol; 2013 Dec; 64(6):941-50. PubMed ID: 23490727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
    Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
    Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.
    Huang KC; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
    Cancer Biol Ther; 2014 Sep; 15(9):1120-8. PubMed ID: 24972028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis.
    Al Bashir S; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
    J Hematol Oncol; 2014 Mar; 7():21. PubMed ID: 24606912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.
    Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort.
    Rubicz R; Zhao S; April C; Wright JL; Kolb S; Coleman I; Lin DW; Nelson PS; Ostrander EA; Feng Z; Fan JB; Stanford JL
    Prostate; 2015 Sep; 75(13):1354-62. PubMed ID: 25990700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center.
    Nie L; Pan X; Zhang M; Yin X; Gong J; Chen X; Xu M; Zhou Q; Chen N
    Prostate; 2019 Jun; 79(8):819-825. PubMed ID: 30900303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERG Expression in Prostate Needle Biopsy: Potential Diagnostic and Prognostic Implications.
    Lee SL; Yu D; Wang C; Saba R; Liu S; Trpkov K; Donnelly B; Bismar TA
    Appl Immunohistochem Mol Morphol; 2015 Aug; 23(7):499-505. PubMed ID: 25517865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer.
    Barros-Silva JD; Ribeiro FR; Rodrigues A; Cruz R; Martins AT; Jerónimo C; Henrique R; Teixeira MR
    Genes Chromosomes Cancer; 2011 Aug; 50(8):662-71. PubMed ID: 21584900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
    Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
    Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
    Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
    Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.